Volume 5.41 | Oct 17

Mammary Cell News 5.41 October 17, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
The Retinoblastoma Tumor Suppressor Pathway Modulates the Invasiveness of ErbB2-Positive Breast Cancer
Researchers demonstrated that retinoblastoma tumor deficiency altered the expression of key molecules needed for proper cellular organization and epithelial cell-cell adhesion as part of a program related to the epithelial-to-mesenchymal transition. [Oncogene] Abstract
Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
PUBLICATIONS (Ranked by impact factor of the journal)

Sequential Application of a Cytotoxic Nanoparticle and a PI3K Inhibitor Enhances Antitumor Efficacy
Researchers engineered a supramolecular cis-platinum nanoparticle, which induced apoptosis in breast cancer cells but also elicited pro-survival signaling via an epidermal growth factor receptor-phosphatidylinositol 3 kinase (PI3K) pathway. [Cancer Res] Abstract

Silencing NOTCH Signaling Causes Growth Arrest in Both Breast Cancer Stem Cells and Breast Cancer Cells
Authors examined the mechanism of action of a small herbal molecule, psoralidin that has been shown to effectively suppress the growth of breast cancer stem cells and breast cancer cells, in breast cancer models. [Br J Cancer] Abstract

MiR-221/-222 Differentiate Prognostic Groups in Advanced Breast Cancers and Influence Cell Invasion
MicroRNA (MiR)-221/-222 expressions were analysed in 86 breast cancer tissues by quantitative RT-PCR and tested for correlation with immunohistochemistry data and clinical follow-up. In vitro assays were conducted using human breast cancer cell lines with lentiviral overexpression of miR-221/-222. [Br J Cancer] Abstract

Reduction of Tumor Angiogenesis Induced by Desmopressin in a Breast Cancer Model
Investigators explored the effects of desmopressin on tumor angiogenesis using the aggressive F3II mammary carcinoma in syngeneic Balb/c mice. [Breast Cancer Res Treat] Full Article

Aspirin-Induced Bcl-2 Translocation and Its Phosphorylation in the Nucleus Trigger Apoptosis in Breast Cancer Cells
Aspirin influenced the formation of a complex by B-cell lymphoma 2 (Bcl-2) and FK506-binding protein 38 and induced the nuclear translocation of Bcl-2 and its phosphorylation. These events inhibited cancer cell proliferation and subsequently enhanced MCF-7 breast cancer cell apoptosis. [Exp Mol Med] Full Article

CDK5 Is Essential for TGF-β1-Induced Epithelial-Mesenchymal Transition and Breast Cancer Progression
Investigators found that cyclin-dependent kinase 5 (CDK5) participated in transforming growth factor-β1 (TGF-β1)-induced epithelial-mesenchymal transition (EMT). In MCF10A, TGF-β1 upregulated the CDK5 and p35 expression, and CDK5 knockdown inhibited TGF-β1-induced EMT. [Sci Rep] Full Article


Randomized Trial of Preoperative Docetaxel with or without Capecitabine After Four Cycles of 5-Fluorouracil-Epirubicin-Cyclophosphamide (FEC) in Early-Stage Breast Cancer: Exploratory Analyses Identify Ki67 as a Predictive Biomarker for Response to Neoadjuvant Chemotherapy
Patients were randomized to four cycles of docetaxel/capecitabine or docetaxel alone after completion of four cycles of FEC. The primary endpoint was the pathological complete response rate. [Breast Cancer Res Treat]
Full Article

Treatment of Older Patients with HER2-Positive Metastatic Breast Cancer with Pertuzumab, Trastuzumab, and Docetaxel: Subgroup Analyses from a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (CLEOPATRA)
Patients who had not received previous chemotherapy or biological therapy for HER2-positive locally recurrent, unresectable or metastatic breast cancer were randomly assigned to treatment with placebo, trastuzumab, and docetaxel or with pertuzumab, trastuzumab, and docetaxel. Primary endpoint was independently assessed progression-free survival. [Breast Cancer Res Treat] Full Article

Association of Positive EBAG9 Immunoreactivity with Unfavorable Prognosis in Breast Cancer Patients Treated with Tamoxifen
Researchers examined immunohistochemical staining of estrogen receptor-binding fragment associated antigen 9 (EBAG9) in 100 breast cancer specimens excised from patients at surgery before tamoxifen treatment. [Clin Breast Cancer] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
New Approaches for Hormone-Receptor Positive Metastatic Breast Cancer
Authors provide the most recent advances in estrogen receptor positive breast cancer, giving emphasis to recently concluded or ongoing trials with the potential to change current clinical practice. [Curr Oncol Rep] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
The Breast Cancer Research Foundation Announces $45 Million in Research Grants
The Breast Cancer Research Foundation® announced its dedication of $45 million to breast cancer research at its annual Symposium and Awards Luncheon. The 2013-2014 grants, awarded to 207 doctors and scientists, build on the foundation’s 20-year commitment to advance the world’s most innovative research and address such critical areas as genetics, immunotherapy, tumor biology, quality of life and metastasis. [Marketwire L.P.] Press Release

PARP Inhibitors May Hold Key to Better HER2-Positive Breast Cancer Treatment
Shih-Hsin Yang, M.D., Ph.D., the Regional Oncology Active Research Southeast Cancer Foundation Endowed Chair in the University of Alabama at Birmingham Department of Radiation Oncology, has received a $450,000 grant from Susan G. Komen for the Cure to further investigate human epidermal growth factor receptor 2 (HER2)-positive breast tumor susceptibility to poly ADP ribose polymerase (PARP) inhibitors. [The University of Alabama at Birmingham] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 6th International Epithelial-Mesenchymal Transition Meeting
November 13-16, 2013
Alicante, Spain

NEW Signaling and Acquired Resistance to Targeted Cancer Therapeutics
January 5-7, 2014
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
NEW PhD Position – Integrated Classification of Breast Cancers to Optimize Treatment Protocols (Radboud University Medical Center)

NEW Postdoctoral Position – Breast Cancer Research (Karolinska Institute)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology and Cancer Genomics (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

Postdoctoral Position – Triple Negative Breast Cancer (Weizmann Institute of Science)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Postdoctoral Fellow – Breast Cancer Biology (Stephenson Cancer Center at the University of Oklahoma)

Research Assistant – Cellular Pathways Involved in Oncogenic Transformation of Breast Epithelial Cells (Mount Sinai School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us